治疗难治性心源性休克的休克团队方法的成本效益。

IF 7.8 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Circulation: Heart Failure Pub Date : 2024-11-01 Epub Date: 2024-10-18 DOI:10.1161/CIRCHEARTFAILURE.124.011709
Iosif Taleb, Theodoros V Giannouchos, Christos P Kyriakopoulos, Antoine Clawson, Erin S Davis, Konstantinos Sideris, Eleni Tseliou, Kevin S Shah, Joseph E Tonna, Elizabeth Dranow, Tara L Jones, Spencer J Carter, James C Fang, Josef Stehlik, Robert L Ohsfeldt, Craig H Selzman, Thomas C Hanff, Stavros G Drakos
{"title":"治疗难治性心源性休克的休克团队方法的成本效益。","authors":"Iosif Taleb, Theodoros V Giannouchos, Christos P Kyriakopoulos, Antoine Clawson, Erin S Davis, Konstantinos Sideris, Eleni Tseliou, Kevin S Shah, Joseph E Tonna, Elizabeth Dranow, Tara L Jones, Spencer J Carter, James C Fang, Josef Stehlik, Robert L Ohsfeldt, Craig H Selzman, Thomas C Hanff, Stavros G Drakos","doi":"10.1161/CIRCHEARTFAILURE.124.011709","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with and without a Shock Team and determine if the team's implementation is cost-effective compared with standard of care.</p><p><strong>Methods: </strong>We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations.</p><p><strong>Results: </strong>The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18-92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; <i>P</i>=0.04 and 55.0% versus 40.5%; <i>P</i>=0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations.</p><p><strong>Conclusions: </strong>The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.</p>","PeriodicalId":10196,"journal":{"name":"Circulation: Heart Failure","volume":" ","pages":"e011709"},"PeriodicalIF":7.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock.\",\"authors\":\"Iosif Taleb, Theodoros V Giannouchos, Christos P Kyriakopoulos, Antoine Clawson, Erin S Davis, Konstantinos Sideris, Eleni Tseliou, Kevin S Shah, Joseph E Tonna, Elizabeth Dranow, Tara L Jones, Spencer J Carter, James C Fang, Josef Stehlik, Robert L Ohsfeldt, Craig H Selzman, Thomas C Hanff, Stavros G Drakos\",\"doi\":\"10.1161/CIRCHEARTFAILURE.124.011709\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with and without a Shock Team and determine if the team's implementation is cost-effective compared with standard of care.</p><p><strong>Methods: </strong>We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations.</p><p><strong>Results: </strong>The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18-92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; <i>P</i>=0.04 and 55.0% versus 40.5%; <i>P</i>=0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations.</p><p><strong>Conclusions: </strong>The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.</p>\",\"PeriodicalId\":10196,\"journal\":{\"name\":\"Circulation: Heart Failure\",\"volume\":\" \",\"pages\":\"e011709\"},\"PeriodicalIF\":7.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Circulation: Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1161/CIRCHEARTFAILURE.124.011709\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Circulation: Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1161/CIRCHEARTFAILURE.124.011709","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/18 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:多学科休克团队改善了心源性休克的临床治疗效果,但尚未对其实施成本进行研究。本研究的目的是比较接受和未接受休克团队治疗的患者的成本,并确定与标准护理相比,团队的实施是否具有成本效益:我们研究了一家三级学术医院在 2009 年至 2018 年期间使用或未使用休克团队治疗的难治性心源性休克患者。我们使用医院的真实数据来比较成本和结果,包括出院时的存活率、1 年存活率和 1 年的质量调整生命年。计算了1年时间跨度内的增量成本效益比,并通过1000次二阶蒙特卡罗模拟进行概率敏感性分析,评估了参数的不确定性:研究涉及 244 名患者,其中 123 人接受休克小组的治疗,121 人接受标准护理。患者主要为男性(77.5%),平均年龄为 58(18-92)岁。休克小组的治疗方法提高了出院存活率和 1 年随访存活率(分别为 61.0% 对 47.9%; P=0.04 和 55.0% 对 40.5%; P=0.03)。与标准护理相比,多学科休克团队提高出院生存概率的增量成本效益比为 102 088 美元。每获得 1 个质量调整生命年,增加 1 年生存概率的增量成本效益比估计为 96 152 美元和 127 862 美元。概率敏感性分析估计结果表明,在大多数以 150 000 美元为支付意愿阈值的模拟中,休克小组都具有成本效益,而在近三分之一的模拟中,休克小组也占主导地位:休克小组治疗难治性心源性休克的方法可能是一种替代传统标准治疗方法的经济有效的方法。这些发现有助于优先实施休克团队计划,进一步改善心源性休克的治疗效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Cost-Effectiveness of a Shock Team Approach in Refractory Cardiogenic Shock.

Background: Multidisciplinary Shock Teams have improved clinical outcomes for cardiogenic shock, but their implementation costs have not been studied. This study's objective was to compare costs between patients treated with and without a Shock Team and determine if the team's implementation is cost-effective compared with standard of care.

Methods: We examined patients with refractory cardiogenic shock treated with or without a Shock Team at a tertiary academic hospital from 2009 to 2018. Real-world hospital data were used to compare costs and outcomes, including survival at discharge, 1-year survival, and quality-adjusted life years gained at 1 year. Incremental cost-effectiveness ratios were calculated over a 1-year time horizon, with parameter uncertainty evaluated through probabilistic sensitivity analysis using 1000 second-order Monte Carlo simulations.

Results: The study involved 244 patients, with 123 treated by the Shock Team and 121 receiving standard of care. Patients were predominantly male (77.5%), with a mean age of 58 (18-92) years. The Shock Team approach improved survival rates at hospital discharge and 1-year follow-up (61.0% versus 47.9%; P=0.04 and 55.0% versus 40.5%; P=0.03, respectively). The incremental cost-effectiveness ratio for increases in survival probability at discharge for the multidisciplinary Shock Team compared with standard of care was $102 088. The incremental cost-effectiveness ratio for increases in survival probability at 1-year was estimated at $96 152 and at $127 862 per 1 quality-adjusted life year gained. Probabilistic sensitivity analysis estimates showed that the Shock Team was cost-effective in the majority of simulations using a willingness-to-pay threshold of $150 000, while it was also dominant in almost one-third of the simulations.

Conclusions: The Shock Team approach for treating refractory cardiogenic shock may be a cost-effective alternative to traditional standard of care. These findings can help prioritize the implementation of Shock Team initiatives to further improve cardiogenic shock outcomes.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Circulation: Heart Failure
Circulation: Heart Failure 医学-心血管系统
CiteScore
12.90
自引率
3.10%
发文量
271
审稿时长
6-12 weeks
期刊介绍: Circulation: Heart Failure focuses on content related to heart failure, mechanical circulatory support, and heart transplant science and medicine. It considers studies conducted in humans or analyses of human data, as well as preclinical studies with direct clinical correlation or relevance. While primarily a clinical journal, it may publish novel basic and preclinical studies that significantly advance the field of heart failure.
期刊最新文献
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction. PRKAG2 Syndrome Caused by a Novel Missense Variant Mimicked Sporadic Hypertrophic Cardiomyopathy Until Its Progression to Burned-Out Phase. Antibody-Mediated Rejection: Beyond the Biopsy. Mineralocorticoid Receptor Antagonists in Heart Failure: An Update. Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1